624 A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy
Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A656-A656
10.1136/jitc-2022-sitc2022.0624